ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

GSK Gsk Plc

1,700.80
-4.40 (-0.26%)
Last Updated: 08:05:01
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Gsk Plc LSE:GSK London Ordinary Share GB00BN7SWP63 ORD 31 1/4P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -4.40 -0.26% 1,700.80 1,700.20 1,701.40 1,703.60 1,699.40 1,701.60 66,397 08:05:01
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 30.33B 4.93B 1.1970 14.25 70.2B

EU Approves GlaxoSmithKline and Genmab's Leukemia Treatment

03/07/2014 3:52pm

Dow Jones News


Gsk (LSE:GSK)
Historical Stock Chart


From Mar 2019 to Mar 2024

Click Here for more Gsk Charts.

By Rory Gallivan

LONDON--The European Union has approved GlaxoSmithKline PLC's (GSK.LN) and Genmab A/S's (GEN.KO) leukemia treatment Arzerra to be used in patients unable to use an alternative drug.

The companies said Thursday that the EU has given marketing permission for Arzerra "as first-line treatment for chronic lymphocytic leukemia in combination with chlorambucil or bendamustine for patients ineligible for fludarabine-based therapy."

Jan van de Winkel, chief executive of Genmab said: "This is another important milestone and we look forward to a successful launch under this new indication of the drug in Europe in the coming months."

-Write to Rory Gallivan at rory.gallivan@wsj.com; Twitter: @RoryGallivan

Subscribe to WSJ: http://online.wsj.com?mod=djnwires


1 Year Gsk Chart

1 Year Gsk Chart

1 Month Gsk Chart

1 Month Gsk Chart

Your Recent History

Delayed Upgrade Clock